SENZIME HAS BEEN APPROVED FOR LISTING ON NASDAQ STOCKHOLM

Uppsala, 23 June 2021. Senzime AB (publ) announces that Nasdaq Stockholm's Listing Committee has approved the company’s application for admission of trading of the company’s shares on Nasdaq Stockholm’s main market. The approval is conditioned upon customary conditions being fulfilled, including the approval and registration of a prospectus by the Swedish Financial Supervisory Authority.

About the list change
The first day of trading on Nasdaq Stockholm’s main market is scheduled for Wednesday 30 June 2021 and the last day of trading on Nasdaq First North Growth Market is scheduled for Tuesday 29 June 2021. The shares will be traded under the same ticker (SEZI) and ISIN-code (SE0002478776). There is no offering or issue of new shares in connection with the list change, and shareholders in Senzime do not need to take any actions.

”The next chapter for Senzime begins as we are approved for listing on Nasdaq Stockholm's main market. This is an important milestone on our mission to eliminate anesthesia-related complications and at the same time build a world-leading company that creates long-term value for customers, shareholders and the society as a whole’’, said Pia Renaudin, CEO of Senzime.

Prospectus
For further information, please refer to the prospectus that has been prepared due to the listing and is expected to be approved and registered by the Swedish Financial Supervisory Authority and published on the company's website well in advance of the first day of trading on Nasdaq Stockholm's main market.

Advisors
Advokatfirman Lindahl has acted as legal advisor in connection with the listing on Nasdaq Stockholm.

For further information, please contact:

Pia Renaudin, CEO of Senzime AB 
Phone: +46 (0) 70-813 34 17, e-post: pia.renaudin@senzime.com
 
Erik Bergman, CFO
Phone: +46 (0) 73-258 81 59, e-mail: erik.bergman@senzime.com

About Senzime

Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 15 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se is Certified Adviser for Senzime. www.senzime.com

Attachments

SENZIME HAS BEEN APPROVED FOR LISTING ON NASDAQ STOCKHOLM

Contact us

Want to know more?

How can Senzime’s innovative patient monitoring solutions help to eliminate in-hospital complications?
Contact us today.

Contact us now